Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Humabs Biomed SA has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner within 1 distinct art unit. This indicates a focused prosecution effort for the company's current biotechnological innovations. The fact that the action is in 1 distinct art unit suggests a consistent application of pharmaceutical examination standards.
JADHAO, SAMADHAN JAISING is the busiest examiner for this portfolio, currently managing 1 pending office action. As the only examiner involved, Jadhao's specific interpretation of biotechnology patent law will be a factor in the outcome of this filing. The 1 pending office action represents the entirety of the company's current active prosecution in this field. This focused prosecution environment allows for a clear and direct path toward resolving the pending matter in the Biotechnology & Pharmaceuticals sector.
For practitioners, the 1 pending office action requires a targeted response that addresses the specific technical issues raised by the examiner. With 1 distinct examiner and 1 distinct art unit, the company can maintain a singular focus on resolving the issues raised in this pending matter. Strategy should be informed by the specific trends and requirements of the Biotechnology & Pharmaceuticals sector. Efficiently navigating the requirements of the 1 distinct art unit will be essential for the company's biotechnological intellectual property strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JADHAO, SAMADHAN JAISING | 1 | 46.9% | +46.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002844 | ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF | JADHAO, SAMADHAN JAISING | 16d overdue |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18002844 | ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF | JADHAO, SAMADHAN JAISING | 1672 | §103 | Non-Final OA | 16d overdue | Pending | Dec 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial